Authors
Latest:
Pipeline Drill-Down: Expert Perspectives on Alzheimer's, Opioids, and CannabisAnalysts from Informa Intelligence take a deeper dive into these three pivotal areas of R&D today-the crisis points and progress.
Latest:
Pipeline Drill-Down: Expert Perspectives on Alzheimer's, Opioids, and CannabisAnalysts from Informa Intelligence take a deeper dive into these three pivotal areas of R&D today-the crisis points and progress.
Latest:
Pipeline Drill-Down: Expert Perspectives on Alzheimer's, Opioids, and CannabisAnalysts from Informa Intelligence take a deeper dive into these three pivotal areas of R&D today-the crisis points and progress.
Latest:
Trust—Biotech’s Hidden AdvantageHow companies can trust now to cultivate corporate reputations that build business.
Latest:
Developing Mindful Pharma LeadersMindfulness is a key factor in enhancing productivity and success in clinical development leaders and the entire pharmaceutical industry.
Latest:
Developing Mindful Pharma LeadersMindfulness is a key factor in enhancing productivity and success in clinical development leaders and the entire pharmaceutical industry.
Latest:
Developing Mindful Pharma LeadersMindfulness is a key factor in enhancing productivity and success in clinical development leaders and the entire pharmaceutical industry.
Latest:
Diabetes Researchers Make Novel Connections with Graph TechnologyEmil Eifrem examines how life science researchers at Munich’s German Center for Diabetes Research are uncovering insights in their data with a new way of working with complex data
Latest:
Machine Learning: The Next Frontier in Commercial PlanningKeshia Vaughn looks at how machine learning can transform commercial planning and outlines what teams will need to deploy it effectively.
Latest:
Ascending the Uncanny Valley in HealthcareBeing more human in brand engagement doesn’t mean being less transparent
Latest:
Securing Medical Devices Means Securing NetworksOrganizations should focus just as much of their attention on securing the actual medical devices they produce as the network they depend on, writes Chris Souza.
Latest:
Reacting to Reference PricingThe industry should take a twin-track approach to the potential threat of the Trump administration's proposed move to reference pricing, writes Todd Edgar.
Latest:
A Match Made in ClinicHow artificial intelligence, wearable devices, and translational informatics are changing healthcare.
Latest:
A Match Made in ClinicHow artificial intelligence, wearable devices, and translational informatics are changing healthcare.
Latest:
5 Ways to Shape a Regulatory Affairs Workforce for the FuturePharmaceutical regulatory divisions should use the same discipline, rigor and focus on the talent pipeline as they do the product pipeline, writes Karin Van Baelen.
Latest:
Measuring the Probability of Pricing and Access SuccessThere is still no structured method of assessing pricing and access risk for drug manufacturers. Presented here is a straightforward measure for integrating pricing and access risk into portfolio planning and decision-making.
Latest:
Commercial Sustainability of Pharmaceutical Innovations for PandemicsAssessing the landscape of the pharma industry’s readiness for future pandemics by looking at past pandemics, funding and revenue, and sustainability.
Latest:
Measuring the Probability of Pricing and Access SuccessThere is still no structured method of assessing pricing and access risk for drug manufacturers. Presented here is a straightforward measure for integrating pricing and access risk into portfolio planning and decision-making.
Latest:
Measuring the Probability of Pricing and Access SuccessThere is still no structured method of assessing pricing and access risk for drug manufacturers. Presented here is a straightforward measure for integrating pricing and access risk into portfolio planning and decision-making.
Latest:
Is Patient Engagement Brexit-Ready?Whatever the final outcome of Brexit, investing in supporting advocacy communities will be an important element of maintaining trusted relationships with patient groups and stakeholders in the UK and the EU, write Nick Hicks and Tamsin Rose.
Latest:
Three Key Dynamics to Understand for Canadian Market AccessThis article discusses three key considerations a manufacturer should either understand or seek a consulting partner to guide them through a commercialization plan.
Latest:
The Biopharma-Led Platform Business Model in HealthcareWhat we can learn from an early leader?
Latest:
Why Pharma Should Pay Attention to Copay Accumulator ProgramsAn understanding of copay accumulator and maximizer benefit design programs.
Latest:
Key Observations on GDPRAs we pass the 6-month anniversary of theGeneral Data Protection Regulation's effective date, the number of organizations which boast 100% GDPR compliance has certainly increased. But life sciences companies are still grappling with implementation of the policy and procedure changes, writes Ashley Williams.
Latest:
Identity Crisis: Data Protection Roles for Life Sciences CompaniesJames Clark addresses one of the key questions data protection and compliance officers are asking following the implementation of the General Data Protection Regulation -"What role am I playing under the GDPR?"
Latest:
Finding the Right Digital Health PartnerPharma companies are increasingly expanding their portfolios into digital health solutions. To find the right partners, there are several key considerations that inform their evaluation and selection.
Latest:
Digital patient solutions: the secret to delivering and securing adoptionIndustry experts cover how to develop digital patient solutions that address real unmet needs and secure adoption.
